talquetamab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
rat origin 5742 2226212-40-2

Description:

MoleculeDescription

Molfile

Synonyms:

  • talquetamab
  • talquetamab-tgvs
  • JNJ-64407564
  • talvey
Talquetamab-tgvs is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T-cells and G protein-coupled receptor class C group 5 member D (GPRC5D) expressed on the surface of multiple myeloma cells and non-malignant plasma cells, as well as healthy tissues such as epithelial cells in keratinized tissues of the skin and tongue. In vitro, talquetamab-tgvs activated T-cells caused the release of proinflammatory cytokines and resulted in the lysis of multiple myeloma cells. Talquetamab-tgvs had anti-tumor activity in mouse models of multiple myeloma.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Aug. 9, 2023 FDA JANSSEN BIOTECH
Aug. 21, 2023 EMA JANSSEN-CILAG INTERNATIONAL N.V.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 435.28 55.53 87 655 27886 90599819
Immune effector cell-associated neurotoxicity syndrome 210.54 55.53 37 705 5731 90621974
Dysgeusia 107.00 55.53 32 710 52528 90575177
Skin exfoliation 59.79 55.53 22 720 67891 90559814

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 390.04 50.96 107 940 44420 42575868
Immune effector cell-associated neurotoxicity syndrome 131.29 50.96 33 1014 9428 42610860
Dysgeusia 116.12 50.96 40 1007 34149 42586139
Skin exfoliation 90.30 50.96 35 1012 41518 42578770
Onychomadesis 66.49 50.96 12 1035 698 42619590
Nail dystrophy 58.78 50.96 10 1037 412 42619876

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 606.00 43.16 148 1362 70158 110517631
Immune effector cell-associated neurotoxicity syndrome 204.64 43.16 46 1464 14736 110573053
Dysgeusia 145.65 43.16 49 1461 69936 110517853
Skin exfoliation 88.14 43.16 36 1474 87615 110500174
Nail dystrophy 66.94 43.16 12 1498 1216 110586573
Plasma cell myeloma 56.95 43.16 24 1486 62912 110524877
Ageusia 45.70 43.16 15 1495 19630 110568159

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FX29 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Other monoclonal antibodies and antibody drug conjugates
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01FX Other monoclonal antibodies and antibody drug conjugates 29 drugs
amivantamabbelantamab mafodotinblinatumomabbrentuximab vedotincatumaxomabdatopotamab deruxtecanelotuzumabelranatamabenfortumab vedotinepcoritamabgemtuzumab ozogamicinglofitamab show all 29 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Relapsed or refractory multiple myeloma indication 109989006 DOID:9538




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
T-cell surface glycoprotein CD3 Surface antigen ANTIBODY BINDING EC50 7.82 DRUG LABEL DRUG LABEL
G-protein coupled receptor family C group 5 member D GPCR ANTIBODY BINDING EC50 6.72 DRUG LABEL DRUG LABEL

External reference:

IDSource
CHEBI:757979 CHEBI
CHEMBL4594503 ChEMBL_ID
C000730985 MESH_SUPPLEMENTAL_RECORD_UI
12240 IUPHAR_LIGAND_ID
DB16678 DRUGBANK_ID
1363065009 SNOMEDCT_US
4042504 VANDF
4042505 VANDF
C5419330 UMLSCUI
11173 INN_ID
370272 MMSL
41893 MMSL
d10092 MMSL
019517 NDDF
D12180 KEGG_DRUG
4W3KFI3TN3 UNII
2644447 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TALVEY HUMAN PRESCRIPTION DRUG LABEL 1 57894-469 INJECTION 3 mg SUBCUTANEOUS BLA 31 sections
TALVEY HUMAN PRESCRIPTION DRUG LABEL 1 57894-469 INJECTION 3 mg SUBCUTANEOUS BLA 31 sections
TALVEY HUMAN PRESCRIPTION DRUG LABEL 1 57894-470 INJECTION 40 mg SUBCUTANEOUS BLA 31 sections
TALVEY HUMAN PRESCRIPTION DRUG LABEL 1 57894-470 INJECTION 40 mg SUBCUTANEOUS BLA 31 sections